Ethic Inc’s Roivant Sciences ROIV Stock Holding History

Ethic Inc’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$471K	Buy	13,312 +4,332	+48%	+$128K	0.01%	964
2026 Q1	$249K	Sell	8,980 -293	-3%	-$7.53K	﹤0.01%	1086
2025 Q4	$201K	Buy	+9,273	New	+$183K	﹤0.01%	1136

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Ethic Inc's ROIV Position: Q2 2026 in Review

Ethic Inc increased its Roivant Sciences (ROIV) stake by 48% in Q2 2026, buying an estimated $128K and bringing the position to 13,312 shares worth $471K. The position accounts for 0.01% of the portfolio, ranked #964.

Ethic Inc first reported a position in ROIV in Q4 2025 and has held it in 3 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Ethic Inc held 13,312 shares of Roivant Sciences worth $471K as of Q2 2026.
Ethic Inc bought 4,332 Roivant Sciences shares in Q2 2026, an estimated $128K.
Roivant Sciences made up 0.01% of Ethic Inc's portfolio in Q2 2026, its #964 holding.
Ethic Inc first reported a position in Roivant Sciences in Q4 2025 and has held it in 3 quarters since.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.